Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson vs adenosine for myocardial perfusion imaging in suspected coronary artery disease
CTR20201171Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of regadenoson in coronary arteriosclerosis, cardiac ischemia, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2020; status: completed.
02
Drugs
regadenoson
03
Conditions
coronary arteriosclerosiscardiac ischemia
Beyond the preview
Go deeper on CTR20201171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201171.